Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort.
Adult
Aged
Anti-Retroviral Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cyclophosphamide
/ administration & dosage
Disease-Free Survival
Doxorubicin
/ administration & dosage
HIV Seropositivity
/ diagnosis
HIV-1
Humans
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Malawi
/ epidemiology
Middle Aged
Prednisone
/ administration & dosage
Prospective Studies
Survival Rate
Vincristine
/ administration & dosage
chemotherapy
diffuse large B-cell lymphoma
human immunodeficiency virus
prognosis
sub-Saharan Africa
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
29
06
2018
accepted:
24
08
2018
pubmed:
20
11
2018
medline:
30
10
2019
entrez:
20
11
2018
Statut:
ppublish
Résumé
Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013-2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty-six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 10
Identifiants
pubmed: 30450671
doi: 10.1111/bjh.15625
pmc: PMC6340743
mid: NIHMS990188
doi:
Substances chimiques
Anti-Retroviral Agents
0
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Clinical Trial
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
364-372Subventions
Organisme : FIC NIH HHS
ID : K01 TW009488
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA190152
Pays : United States
Organisme : NCI NIH HHS
ID : P20 CA210285
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016086
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA233709
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA121947
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009340
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA180815
Pays : United States
Informations de copyright
© 2018 British Society for Haematology and John Wiley & Sons Ltd.
Références
J Acquir Immune Defic Syndr. 2011 Apr;56(4):312-9
pubmed: 21350364
Pediatr Blood Cancer. 2017 Jun;64(6):
pubmed: 27896944
Am J Clin Pathol. 2016 Oct;146(4):423-30
pubmed: 27594430
AIDS. 2017 Nov 28;31(18):2493-2501
pubmed: 28926410
AIDS. 2015 Apr 24;29(7):811-8
pubmed: 25730510
Clin Infect Dis. 2014 Jul 15;59(2):279-86
pubmed: 24755860
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241264
AIDS. 2014 Mar 13;28(5):689-97
pubmed: 24418826
J Glob Oncol. 2016 Aug 31;3(3):218-226
pubmed: 28717763
J Natl Cancer Inst. 2013 Aug 21;105(16):1221-9
pubmed: 23892362
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Blood. 2010 Apr 15;115(15):3008-16
pubmed: 20023215
Infect Agent Cancer. 2017 Aug 9;12:45
pubmed: 28808480
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):66-73
pubmed: 23797692
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
J Clin Oncol. 2009 Jul 20;27(21):3480-8
pubmed: 19470940
Am J Case Rep. 2015 Jun 05;16:347-52
pubmed: 26046822
PLoS One. 2016 Mar 02;11(3):e0150445
pubmed: 26934054
Br J Haematol. 2011 Sep;154(6):696-703
pubmed: 21707579
Haematologica. 2014 Nov;99(11):1731-7
pubmed: 25150257
BMC Clin Pathol. 2009 Dec 16;9:11
pubmed: 20003543
Transfus Apher Sci. 2007 Aug;37(1):93-102
pubmed: 17931976
Blood. 2010 Apr 15;115(15):3017-24
pubmed: 20130244
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Haematologica. 2005 May;90(5):704-6
pubmed: 15921395